THRD

Companies
NASDAQ
Third Harmonic Bio, Inc.
Health Care
Price Chart
Overview

About THRD

Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.

Market Cap
$581.9M
Volume
1.6M
Avg. Volume
4.6M
P/E Ratio
-3.3636363
Dividend Yield
0.00%
Employees
28.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
0.31
Low Correlation
Volatility
High (0.84)
Relative to market

Macro Factor Sensitivities

Interest Rates
Medium Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for THRD.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, THRD shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$581.9M
Volume1.6M
P/E Ratio-3.36
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 8, 2025
Related Securities

PortfolioPilot Analysis

Get AI-powered insights on how THRD fits into your investment strategy and portfolio diversification.

Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025